FY2024 EPS Estimates for GeoVax Labs Lifted by Roth Capital

GeoVax Labs, Inc. (NASDAQ:GOVX) – Investment analysts at Roth Capital increased their FY2024 EPS estimates for shares of GeoVax Labs in a research note issued on Tuesday, November 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($4.30) for the year, up from their previous forecast of ($5.52). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q4 2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $8.55 EPS.

Other research analysts have also issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Monday, August 12th. EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Noble Financial upped their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th. Finally, Alliance Global Partners started coverage on shares of GeoVax Labs in a research note on Monday. They issued a “buy” rating and a $15.00 price target for the company. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Stock Down 3.3 %

NASDAQ GOVX opened at $2.61 on Friday. The company has a 50-day simple moving average of $2.42 and a 200-day simple moving average of $2.59. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same period last year, the firm posted ($4.80) earnings per share.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.